BPG is committed to discovery and dissemination of knowledge
Articles Published Processes
12/20/2024 3:53:47 AM | Browse: 175 | Download: 615
 |
Received |
|
2024-07-05 07:59 |
|
Peer-Review Started |
|
2024-07-05 07:59 |
|
First Decision by Editorial Office Director |
|
2024-11-10 06:04 |
|
Return for Revision |
|
2024-11-10 06:04 |
|
Revised |
|
2024-11-18 15:30 |
 |
Publication Fee Transferred |
|
|
|
Second Decision by Editor |
|
2024-12-02 02:38 |
|
Second Decision by Editor-in-Chief |
|
|
|
Final Decision by Editorial Office Director |
|
2024-12-02 05:55 |
|
Articles in Press |
|
2024-12-02 05:55 |
|
Edit the Manuscript by Language Editor |
|
|
|
Typeset the Manuscript |
|
2024-12-12 07:59 |
|
Publish the Manuscript Online |
|
2024-12-20 03:53 |
| ISSN |
1007-9327 (print) and 2219-2840 (online) |
| Open Access |
This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/Licenses/by-nc/4.0/ |
| Copyright |
© The Author(s) 2024. Published by Baishideng Publishing Group Inc. All rights reserved. |
| Article Reprints |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
|
| Permissions |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
|
| Publisher |
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA |
| Website |
http://www.wjgnet.com |
| Category |
Pharmacology & Pharmacy |
| Manuscript Type |
Letter to the Editor |
| Article Title |
Elafibranor: A promising therapeutic approach for liver fibrosis and gut barrier dysfunction in alcohol-associated liver disease
|
| Manuscript Source |
Invited Manuscript |
| All Author List |
Chun-Han Cheng, Wen-Rui Hao and Tzu-Hurng Cheng |
| ORCID |
|
| Funding Agency and Grant Number |
|
| Corresponding Author |
Tzu-Hurng Cheng, PhD, Professor, Department of Biochemistry, School of Medicine, College of Medicine, China Medical University, No. 91 Xueshi Road, North District, Taichung 404328, Taiwan. thcheng@mail.cmu.edu.tw |
| Key Words |
Elafibranor; Liver fibrosis; Gut barrier function; Alcohol-associated liver disease; Peroxisome proliferator-activated receptor agonists |
| Core Tip |
This article highlights the major findings of the study written by Koizumi et al. The study demonstrated the potential of elafibranor, a peroxisome proliferator-activated receptor agonist, in mitigating liver fibrosis and improving gut barrier integrity in a mouse model of alcohol-associated liver disease. These findings underscore the promising therapeutic potential of elafibranor and its relevance in advancing treatment strategies for liver diseases linked to chronic alcohol consumption. |
| Publish Date |
2024-12-20 03:53 |
| Citation |
Cheng CH, Hao WR, Cheng TH. Elafibranor: A promising therapeutic approach for liver fibrosis and gut barrier dysfunction in alcohol-associated liver disease. World J Gastroenterol 2025; 31(3): 98783 |
| URL |
https://www.wjgnet.com/1007-9327/full/v31/i3/98783.htm |
| DOI |
https://dx.doi.org/10.3748/wjg.v31.i3.98783 |
All content on this site: Copyright © 1993-2026 Baishideng Publishing Group Inc, its licensors, and contributors. All rights are reserved, including those for text and data mining, AI training, and similar technologies. For all open access content, the relevant licensing terms apply.
